DUBLIN, March 29, 2021 /PRNewswire/ -- The "Fiducial Markers Market by Cancer Type, Product, End User, Modality and Geography - Global Drivers, Restraints, Opportunities, Trends, and Forecast up to 2026" report has been added to ResearchAndMarkets.com's offering.
Fiducial Markers Market is predicted to grow at a CAGR of 4.90% with a market value in 2026.
Fiducial markers are the tiny objects placed in or near a tumor to spot the area that needs to get surgery. These markers are designed to spot the precise position of the tumor and assist the doctor in providing the radiation on that specified area because the radiation can damage the other tissues.
These fiducial markers are widely used in cancer treatment, where radiotherapy is performed. Dramatically increasing cases of cancer, growing favorable reimbursements, and rapidly growing investments in the cancer research and development sector are the few significant factors that are contributing to the market growth. But somehow, the substitute therapies for radiotherapy and the expensive costs for the fiducial markers are making the market drawback.
Based on cancer type, the market can be divided into Prostate Cancer, Lung Cancer, Breast Cancer, Gastric Cancer, and Other Cancers. Among all cancer types, the prostate cancer can be taken as the most affected cancer, and it is dominating the market share due to the changing modern life and extension of healthcare framework and increased capabilities of research.
Fiducial markers based on the product is categorized into metal-based markers and other fiducial markers. Metal-based markers are the most used markers in this process of radiotherapy, and the metal-based markers are further divided into pure gold, gold alloys, and other metal-based markers. Pure gold markers are very effective in this segment as these markers are immovable and do not react to the tissues.
As per the end-users, the fiducial markers market is separated into hospitals and outpatient, independent radiotherapy centers, and cancer research centers. The hospitals and outpatient segment is anticipated to have a major share in the market growth due to the improvised facilities in the hospitals and outpatient care. Further, the fiducial markers included in radiotherapy is a relatively less critical process, which is more suitable in outpatient care.
The ultrasound modality segment plays a major role on the basis of modality in the fiducial markers market. Because the ultrasound is the less harmful method compared to all modalities as in most cases, people prefer less invasive procedures.
As per the geography, the fiducial markers market is segregated into majorly four regions-North America, Europe, Asia Pacific, and the Rest of the World. North America accounted for the largest share in the market because of the potential companies present in this region and in addition, the growing adoption of the latest radiotherapy treatment in the healthcare centers in North America.
In this scenario, of globally increasing prevalence of cancer is the major attribute to support market growth. The other lucrative factors contributing to the fiducial markers market growth such as, not only in developed countries but also the developing countries are concentrating on the favorable reimbursements. Nonetheless, the lack of skilled professionals in this field is a challenge for the fiducial markers market.
CIVCO RADIOTHERAPY, Boston Scientific Corporation, IZI Medical Products, IBA, Naslund Medical AB, Medtronic, Best Medical International, Inc., Nanovi A/S, Carbon Medical Technologies, Eckert & Ziegler., Innovative Oncology Solutions, QlRad Inc, Stellar Medical, JJ-Medtech, QFIX, Varian Medical Systems, Inc, Beekley Corporation, Innomedicus Ag, Meditronix Corporation and Seedos Ltd. These are the companies that are leading the market.
Therefore, the fiducial markers act as a significant role in cancer treatment. Furthermore, the stakeholders in the emerging markets are also investing heavily for the better improvement of the healthcare centers in the respective countries, thus enabling further growth in the market. The fiducial markers market report gives the PEST analysis of the regions expresses the micro-environmental factors.
Key Topics Covered:
1. Executive Summary
2. Industry Outlook
2.1. Industry Overview
2.2. Industry Trends
3. Market Snapshot
3.1. Market Definition
3.2. Market Outlook
3.3. PEST Analysis
3.4. Porter Five Forces
3.5. Related Markets
4. Market characteristics
4.1. Market Evolution
4.2. Market Trends and Impact
4.3. Advantages/Disadvantages of Market
4.4. Regulatory Impact
4.5. Market Offerings
4.6. Market Segmentation
4.7. Market Dynamics
4.7.1. Drivers
4.7.2. Restraints
4.7.3. Opportunities
4.8. DRO - Impact Analysis
5. Cancer Type: Market Size & Analysis
5.1. Overview
5.2. Prostate Cancer
5.3. Lung Cancer
5.4. Breast Cancer
5.5. Gastric Cancer
5.6. Other Cancers
6. Product: Market Size & Analysis
6.1. Overview
6.2. Metal-based Markers
6.2.1. Pure Gold
6.2.2. Gold Alloys
6.2.3. Other Metal-based Markers
6.3. Other Fiducial Markers
7. End-User: Market Size & Analysis
7.1. Overview
7.2. Hospitals & Outpatient Facilities
7.3. Independent Radiotherapy Centers
7.4. Cancer Research Centers
8. Modality: Market Size & Analysis
8.1. Overview
8.2. CT/CBCT
8.3. MRI
8.4. Ultrasound
8.5. Radiotherapy
9. Geography: Market Size & Analysis
9.1. Overview
9.2. North America
9.3. Europe
9.4. Asia Pacific
9.5. Rest of the World
10. Competitive Landscape
10.1. Competitor Comparison Analysis
10.2. Market Developments
10.3. Mergers and Acquisitions, Legal, Awards, Partnerships
10.4. Product Launches and execution
11. Vendor Profiles
11.1. CIVCO RADIOTHERAPY
11.1.1. Overview
11.1.2. Product Offerings
11.1.3. Geographic Revenue
11.1.4. Business Units
11.1.5. Developments
11.1.6. Business Strategy
11.2. Boston Scientific Corporation
11.3. IZI Medical Products
11.4. IBA
11.5. Naslund Medical AB.
11.6. Medtronic
11.7. Best Medical International, Inc
11.8. Nanovi A/S
11.9. Carbon Medical Technologies
11.10. Eckert & Ziegler
12. Companies to Watch
12.1. Innovative Oncology Solutions.
12.1.1. Overview
12.1.2. Market
12.1.3. Business Strategy
12.2. QlRad Inc
12.3. Stellar Medical.
12.4. JJ-Medtech
12.5 Innovative Oncology Solutions
For more information about this report visit https://www.researchandmarkets.com/r/ejcxo8
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article